Menu
doctor's visit, prostate cancer
DRUG GUIDE

Real Talk Rx: Cabenuva®

Your guide to Cabenuva for the treatment of HIV
Brand Name: Cabenuva
Generic Name: cabotegravir and rilpivirine
Drug Class: Complete long-acting injectable — Integrase strand transfer inhibitor plus a non-nucleoside reverse transcriptase inhibitor (INSTI + NNRTI)

Cabenuva is a complete HIV treatment regimen in a once-a-month or once-every-two-months injection. Combining two HIV medicines, cabotegravir and rilpivirine, it attacks the virus at different points in its life cycle. Cabenuva is made by ViiV Healthcare and was FDA-approved in January 2021 for monthly dosing and in February 2022 for bimonthly dosing. Cabenuva does not cure HIV, but when taken on schedule, it can suppress HIV to undetectable levels. Cabenuva is meant to replace a current HIV regimen that is already under control, not for those whose virus is not suppressed. 

Who Can Take Cabenuva?

Cabenuva may be prescribed for the treatment of HIV in:

  • Adults and children 12 and older and at least 77 pounds
  • People whose virus is currently suppressed (undetectable) on a stable regimen with no history of treatment failure or resistance to cabotegravir and rilpivirine
  • People with undetectable HIV status who want to switch from a daily pill to monthly/bimonthly injections

How Does Cabenuva Work?

Cabotegravir, the INSTI in Cabenuva, blocks the enzyme that the virus uses to harm your CD4 cells, thus helping to protect your immune system. Without the enzyme, the virus can’t make copies of itself. 

The NNRTI rilpivirine blocks reverse transcriptase, an enzyme HIV uses to make copies of its genetic material.

Both medicines are made to be extended-release suspensions that are injected into the muscles of the buttocks and release into the bloodstream over several weeks, meaning you’ll only need the injections at your regular appointments rather than every day.

How Is Cabenuva Taken?

Cabenuva is given to you by a healthcare provider as an intramuscular shot in each buttock during the same visit. It is not self-injected.

Before starting injections, some people first take two tablets, one containing cabotegravir and one containing rilpivirine, once a day for about a month to check how they tolerate the medicines. This oral lead-in is optional, and some people go straight from their current HIV regimen to injections.

Cabenuva dosing is as follows:

  • A 600 mg (3 mL) injection of cabotegravir and a 900 mg (3 mL) injection of rilpivirine
  • A monthly, smaller 400 mg/600 mg dose or
  • A 600 mg/900 mg starter dose that continues every two months after that

There is a flexible 7-day treatment window before or after your next scheduled injection appointment.

What Does the Research Show?

Sixteen percent of the participants in the FLAIR and ATLAS-2M phase 3 clinical trials for Cabenuva were Black or African descent. Over the course of 96 weeks, overall HIV suppression rates ranged from 83 to 94 percent across all racial groups, and treatment failure and serious side effects were low and similar between groups. Across all races, treatment satisfaction scores were up. ATLAS-2M also showed that the every-two-month dosing worked as well as the monthly dose.

The ongoing BEYOND study tracking people who switched to Cabenuva revealed that 98 percent have remained undetectable for 24 months and only 2 percent stopped due to injection site reactions.

Common Side Effects of Cabenuva

Possible side effects include:

  • Pain, swelling, redness, itching, bruising, warmth, or a hardened lump at the injection site the most common side effect, usually mild to moderate and improving within a few days
  • Fever
  • Fatigue or tiredness
  • Headache
  • Muscle or bone pain
  • Nausea
  • Trouble sleeping
  • Dizziness
  • Rash

Serious Side Effects of Cabenuva

Seek medical treatment right away for: 

  • Trouble breathing, wheezing, dizziness, flushing, sweating, numbness around the mouth, chest or back pain, or a change in blood pressure within minutes of the rilpivirine injection – your provider may ask you to stay for about 10 minutes after your shot to watch for this
  • Yellowing of the skin or the whites of the eyes, dark urine, light-colored stools, loss of appetite, nausea, or pain on the right side of your stomach – which could be signs of liver trouble
  • A severe rash, especially with fever, blistering, or swelling of the face, lips, or tongue
  • New or worsening depression, mood changes, or thoughts of suicide
  • Fever, swollen glands, or symptoms of an old infection flaring up as your immune system recovers

Special Precautions

The importance of staying on schedule

Cabenuva can stay in your body for up to a year or longer after your last injection, but that is not an excuse to miss or skip doses. If you need to stop Cabenuva for any reason, your doctor will place you on a different suppressive HIV regimen soon after your last dose (within about a month if you were on monthly dosing, or two months if you were on the every-two-months schedule) so the virus doesn’t get a chance to resist the medication.

What Should You Discuss With Your Doctor?

Cabenuva should never be taken with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin, rifampin, rifabutin, or rifapentine; more than a single dose of dexamethasone; or the herbal supplement St. John’s wort. Always tell your doctor about every medication, supplement, herbal product, and over-the-counter drug you take so they can check for these interactions before you start Cabenuva.

Tell your healthcare provider if you have:

  • Hepatitis B or hepatitis C infection, now or in the past
  • Any liver problems
  • A history of depression, suicidal thoughts, or other mental health conditions
  • A known allergy to cabotegravir or rilpivirine
  • Plans to become pregnant, or if you are pregnant or breastfeeding

Why This Matters for Black Patients

Black people tend to be hit the hardest with HIV, making up 39 percent of new HIV diagnoses in 2024, despite being only 12 percent of the U.S. population. Black people with HIV are also among the least likely of any race to receive medical care within a month of diagnosis. Gaps in treatment can stem from insurance coverage, transportation, housing instability, provider bias, and medical mistrust. Needing a monthly or bimonthly clinic visit can add another hurdle for Black patients compared to a daily take-anywhere pill.

It is also worth noting that the weight gain observed in Black women on certain HIV medications can be a potential drawback, since Black people already face hypertension, diabetes, and heart disease. Don’t be afraid to ask your provider about your options if this is a concern.

What Savings and Support Programs Are Available?

ViiV Healthcare offers the ViiVConnect Copay Program that brings your out-of-pocket cost for Cabenuva as low as $0 a month if you have private or commercial insurance. This copay program is unavailable to people enrolled in Medicare, Medicaid, or other government drug programs. If you are uninsured or underinsured, ViiVConnect can help you look into more assistance options. Call 1-844-588-3288 or visit viivconnect.com for more information.

Outside of ViiV Healthcare’s program, every state has an AIDS Drug Assistance Program (ADAP) that helps cover HIV medication costs for those who are uninsured or underinsured and meet certain income limits.

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking any drug or commencing or discontinuing any course of treatment.

References
  1. U.S. Food and Drug Administration. FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. January 21–22, 2021. https://www.hiv.gov/blog/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv 
  2. Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months. PR Newswire, February 1, 2022. https://www.prnewswire.com/news-releases/us-fda-approves-cabenuva-rilpivirine-and-cabotegravir-for-use-every-two-months-expanding-the-label-of-the-first-and-only-long-acting-hiv-treatment-301473178.html 
  3. U.S. Food and Drug Administration / DailyMed. CABENUVA (cabotegravir and rilpivirine) full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36 ; https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212888s015lbl.pdf  (covers indication, dosing, mechanism of action, contraindications, warnings, and adverse reactions)
  4. van Wyk JA, Patel P, Elliot E, D'Amico R, et al. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race. Open Forum Infect Dis. 2022;9(Suppl 2):ofac492.109. https://pmc.ncbi.nlm.nih.gov/articles/PMC9751827/ 
  5. Overton E, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M): a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet. 2020;396(10267):1994–2005. https://pubmed.ncbi.nlm.nih.gov/33308425/ 
  6. ViiV Healthcare. CABENUVA Clinical Trials — BEYOND real-world study results. https://www.cabenuva.com/about/clinical-studies/ 
  7. Blick G, Santiago-Colon L, Richardson D, et al. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). 13th IAS Conference on HIV Science, July 2025; reported in Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/real-world-study-finds-cabenuva-outcomes-similar-to-clinical-trials-ias-2025 
  8. Centers for Disease Control and Prevention. HIV Diagnoses, Deaths, and Prevalence (2024 data). https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html 
  9. Centers for Disease Control and Prevention. National HIV Prevention and Care Objectives: 2026 Update (2024 surveillance data). Published May 18, 2026. https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2026.html 
  10. Bourgi K, Bian A, Boyd L, Gupta SK, et al., for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada. The Journal of Infectious Diseases. 2026;jiag271. https://doi.org/10.1093/infdis/jiag271 
  11. ViiV Healthcare. Discover Savings & Support — CABENUVA (ViivConnect Copay Program). https://www.cabenuva.com/savings-and-support/cabenuva-support/ 
  12. Health Resources and Services Administration (Ryan White HIV/AIDS Program). Part B: AIDS Drug Assistance Program (ADAP). https://ryanwhite.hrsa.gov/about/parts-and-initiatives/part-b-adap 
  13. ViiV Healthcare. Frequently Asked Questions. CABENUVA official site. https://www.cabenuva.com/savings-and-support/faqs/ 
  14. Cabenuva Dosage Guide. Drugs.com. https://www.drugs.com/dosage/cabenuva.html 
  15. Centers for Disease Control and Prevention. HIV Treatment as Prevention. https://www.cdc.gov/hivpartners/php/hiv-treatment/index.html 

Frequently Asked Questions

More from this guide

Answer the question below
What resources do you need the most as a caregiver?

Where Culture Meets Care

BlackDoctor is the world’s largest and most comprehensive online health resource specifically for the Black community. BlackDoctor understands that the uniqueness of Black culture - our heritage and our traditions - plays a role in our health. BlackDoctor gives you access to innovative new approaches to the health information you need in everyday language so you can break through the disparities, gain control and live your life to its fullest.
✦ AI Search Disclaimer
This AI-powered search tool helps you find relevant health articles from the BlackDoctor.org archive. Please keep the following in mind:
✦ For Informational Purposes Only
The information provided through this AI search is for general educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment.
✦ Always Consult a Healthcare Provider
Never disregard professional medical advice or delay seeking it because of something you have read through this search tool. If you have a medical emergency, call your doctor or 911 immediately.
✦ AI Limitations
This search tool uses artificial intelligence to help match your queries with articles in our archive. While we strive for accuracy, AI-generated results may occasionally be incomplete, outdated, or not fully relevant to your specific situation.
✦ No Doctor-Patient Relationship
Using this search tool does not create a doctor-patient relationship between you and BlackDoctor.org or any healthcare provider.
Explore over 35,000 articles and videos across black health, wellness, lifestyle and culture
Full AI Search Experience >